Research: Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada

Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis – Circulation: Cardiovascular Quality and Outcomes (free)

Commentaries: Generic Blood Pressure Drugs May Be Tied to Increase in Adverse Events – Physician’s First Watch (free) AND Generic ARBs Linked to Increased Adverse Events – TCTMD (free)

As in any observational study, association does not necessarily imply causation.